دورية أكاديمية
CSF Chitinase 3–Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis
| العنوان: | CSF Chitinase 3–Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis |
|---|---|
| المؤلفون: | Comabella, Manuel, Sastre Garriga, Jaume, Borràs, Eva, Villar, Luisa M., Saiz Hinarejos, Albert, Martínez Yélamos, Sergio, García Merino, Juan Antonio, Pinteac, Rucsanda, Fissolo, Nicolás, Sánchez López, Antonio J., Costa Frossard, Lucienne, Blanco, Yolanda, Llufriu Duran, Sara, Vidal Jordana, Ángela, Sabidó Aguadé, Eduard, Montalbán Gairín, Xavier |
| المصدر: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
| بيانات النشر: | Ovid Technologies (Wolters Kluwer Health) |
| سنة النشر: | 2021 |
| المجموعة: | Dipòsit Digital de la Universitat de Barcelona |
| مصطلحات موضوعية: | Esclerosi múltiple, Marcadors bioquímics, Estudi de casos, Multiple sclerosis, Biochemical markers, Case studies |
| الوصف: | Objective: This study aimed to identify long-term prognostic protein biomarkers associated with disease progression in patients with progressive multiple sclerosis (MS). Methods: CSF samples were collected from a discovery cohort of 28 patients with progressive MS who participated in a clinical trial with interferon beta. Patients were classified into high and low disability progression phenotypes according to numeric progression rates (NPR) and step-based progression rates (SPR) after a mean follow-up time of 12 years. Protein abundance was measured by shotgun proteomics. Selected proteins from the discovery cohort were quantified by parallel reaction monitoring in CSF samples from an independent validation cohort of 41 patients with progressive MS classified also into high and low disability progression phenotypes after a mean follow-up time of 7 years. Results: Of 2,548 CSF proteins identified in the discovery cohort, 10 were selected for validation based on their association with long-term disability progression: SPATS2-like protein, chitinase 3-like 2 (CHI3L2), plasma serine protease inhibitor, metallothionein-3, phospholipase D4, beta-hexosaminidase, neurexophilin-1, adipocyte enhancer-binding protein 1, cathepsin L1, and lipopolysaccharide-binding protein. Only CHI3L2 was validated, and patients with high disability progression exhibited significantly higher CSF protein levels compared with patients with low disability progression (p = 0.03 for NPR and p = 0.02 for SPR). CHI3L2 levels showed good performance to discriminate between high and low disability progression in patients with progressive MS (area under the curve 0.73; sensitivity 90% and specificity 63%). Conclusions: Although further confirmatory studies are needed, we propose CSF CHI3L2 as a prognostic protein biomarker associated with long-term disability progression in patients with progressive MS. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 34497102 |
| العلاقة: | Reproducció del document publicat a: https://doi.org/10.1212/NXI.0000000000001082Test; Neurology - Neuroimmunology Neuroinflammation, 2021, vol. 8, num. 6, p. e1082; https://doi.org/10.1212/NXI.0000000000001082Test; http://hdl.handle.net/2445/181334Test |
| الإتاحة: | https://doi.org/10.1212/NXI.0000000000001082Test http://hdl.handle.net/2445/181334Test |
| حقوق: | cc-by-nc-nd (c) Comabella, Manuel et al., 2021 ; http://creativecommons.org/licenses/by-nc-nd/4.0Test/ ; info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.5899D1E0 |
| قاعدة البيانات: | BASE |
| تدمد: | 34497102 |
|---|